Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Variants of the interleukin-1 receptor antagonist gene are associated with fat mass in men

A Corrigendum to this article was published on 15 June 2009



Immune functions seem to have connections to variations in body fat mass. Studies of knockout mice indicate that endogenous interleukin (IL)-1 can suppress mature-onset obesity.


To systematically investigate our hypotheses that single-nucleotide polymorphisms (SNPs) and/or haplotypes variants in the IL-1 gene system are associated with fat mass.


The Gothenburg osteoporosis and obesity determinants (GOOD) study is a population-based cross-sectional study of 18–20 year-old men (n=1068), from Gothenburg, Sweden. Major findings were confirmed in elderly men (n=3014) from the Swedish part of the osteoporotic fractures in men (MrOS) multicenter population-based study.

Main Outcome Measure:

The genotype distributions and their association with body fat mass in different compartments, measured with dual-energy X-ray absorptiometry (DXA).


Out of 15 investigated SNPs in the IL-1 receptor antagonist (IL1RN) gene, a recently identified 3′ untranslated region C>T (rs4252041, minor allele frequency=4%) SNP was associated with the primary outcome total fat mass (P=0.003) and regional fat masses, but not with lean body mass or serum IL-1 receptor 1 (IL1RN) levels. This SNP was also associated with body fat when correcting the earlier reported IL1RN+2018 T>C (rs419598) SNP (in linkage disequilibrium with a well-studied variable number tandem repeat of 86 bp). The association between rs4252041 SNP and body fat was confirmed in the older MrOS population (P=0.03). The rs4252041 SNP was part of three haplotypes consisting of five adjacent SNPs that were identified by a sliding window approach. These haplotypes had a highly significant global association with total body fat (P<0.001). None of the other investigated members of the IL-1 gene family displayed any SNPs that have not been described previously to be significantly associated with body fat.


The IL1RN gene, shown to enhance obesity by suppressing IL-1 effects in experimental animals, have no previously described gene polymorphisms and haplotypes that are associated with fat, but not lean mass in two populations of men.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2


  1. Rafiq S, Stevens K, Hurst AJ, Murray A, Henley W, Weedon MN et al. Common genetic variation in the gene encoding interleukin-1-receptor antagonist (IL-1RA) is associated with altered circulating IL-1RA levels. Genes Immun 2007; 8: 344–351.

    Article  CAS  Google Scholar 

  2. Gabay C, Smith MF, Eidlen D, Arend WP . Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest 1997; 99: 2930–2940.

    Article  CAS  Google Scholar 

  3. Juge-Aubry CE, Somm E, Giusti V, Pernin A, Chicheportiche R, Verdumo C et al. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes 2003; 52: 1104–1110.

    Article  CAS  Google Scholar 

  4. Somm E, Cettour-Rose P, Asensio C, Charollais A, Klein M, Theander-Carrillo C et al. Interleukin-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity in rodents. Diabetologia 2006; 49: 387–393.

    Article  CAS  Google Scholar 

  5. Arend WP . The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002; 13: 323–340.

    Article  CAS  Google Scholar 

  6. Dinarello CA . The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 2000; 343: 732–734.

    Article  CAS  Google Scholar 

  7. Dinarello CA . Blocking IL-1 in systemic inflammation. J Exp Med 2005; 201: 1355–1359.

    Article  CAS  Google Scholar 

  8. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517–1526.

    Article  CAS  Google Scholar 

  9. Maedler K, Sergeev P, Ehses JA, Mathe Z, Bosco D, Berney T et al. Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci USA 2004; 101: 8138–8143.

    Article  CAS  Google Scholar 

  10. Mandrup-Poulsen T . The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996; 39: 1005–1029.

    Article  CAS  Google Scholar 

  11. Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M . Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 1986; 232: 1545–1547.

    Article  CAS  Google Scholar 

  12. Chida D, Osaka T, Hashimoto O, Iwakura Y . Combined interleukin-6 and interleukin-1 deficiency causes obesity in young mice. Diabetes 2006; 55: 971–977.

    Article  CAS  Google Scholar 

  13. Garcia MC, Wernstedt I, Berndtsson A, Enge M, Bell M, Hultgren O et al. Mature-onset obesity in interleukin-1 receptor I knockout mice. Diabetes 2006; 55: 1205–1213.

    Article  CAS  Google Scholar 

  14. Somm E, Henrichot E, Pernin A, Juge-Aubry CE, Muzzin P, Dayer JM et al. Decreased fat mass in interleukin-1 receptor antagonist-deficient mice: impact on adipogenesis, food intake, and energy expenditure. Diabetes 2005; 54: 3503–3509.

    Article  CAS  Google Scholar 

  15. Matsuki T, Horai R, Sudo K, Iwakura Y . IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J Exp Med 2003; 198: 877–888.

    Article  CAS  Google Scholar 

  16. Strandberg L, Lorentzon M, Hellqvist A, Nilsson S, Wallenius V, Ohlsson C et al. Interleukin-1 system gene polymorphisms are associated with fat mass in young men. J Clin Endocrinol Metab 2006; 91: 2749–2754.

    Article  CAS  Google Scholar 

  17. Strandberg L, Mellström D, Ljunggren Ö, Grundberg E, Karlsson MK, Holmberg AH et al. IL6 and IL1B polymorphisms are associated with fat mass in older men: the MrOS Study Sweden. Obesity (Silver Spring) 2008; 16: 710–713.

    Article  CAS  Google Scholar 

  18. Lorentzon M, Mellström D, Ohlsson C . Age of attainment of peak bone mass is site specific in Swedish men—The GOOD study. J Bone Miner Res 2005; 20: 1223–1227.

    Article  Google Scholar 

  19. Mellström D, Johnell O, Ljunggren Ö, Eriksson AL, Lorentzon M, Mallmin H et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res 2006; 21: 529–535.

    Article  Google Scholar 

  20. Fan JB, Oliphant A, Shen R, Kermani BG, Garcia F, Gunderson KL et al. Highly parallel SNP genotyping. Cold Spring Harb Symp Quant Biol 2003; 68: 69–78.

    Article  CAS  Google Scholar 

  21. Barrett JC, Fry B, Maller J, Daly MJ . Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263–265.

    Article  CAS  Google Scholar 

  22. Donath MY, Storling J, Berchtold LA, Billestrup N, Mandrup-Poulsen T . Cytokines and beta-cell biology: from concept to clinical translation. Endocr Rev 2008; 29: 334–350.

    Article  CAS  Google Scholar 

  23. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002; 8: 75–79.

    Article  CAS  Google Scholar 

  24. Wisse BE, Ogimoto K, Morton GJ, Williams DL, Schwartz MW . Central interleukin-1 (IL1) signaling is required for pharmacological, but not physiological, effects of leptin on energy balance. Brain Res 2007; 1144: 101–106.

    Article  CAS  Google Scholar 

  25. Luheshi GN, Gardner JD, Rushforth DA, Loudon AS, Rothwell NJ . Leptin actions on food intake and body temperature are mediated by IL-1. Proc Natl Acad Sci U S A 1999; 96: 7047–7052.

    Article  CAS  Google Scholar 

  26. Meier CA, Bobbioni E, Gabay C, Assimacopoulos-Jeannet F, Golay A, Dayer JM . IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab 2002; 87: 1184–1188.

    Article  CAS  Google Scholar 

  27. Wisse BE, Ogimoto K, Schwartz MW . Role of hypothalamic interleukin-1beta (IL-1beta) in regulation of energy homeostasis by melanocortins. Peptides 2006; 27: 265–273.

    Article  CAS  Google Scholar 

  28. Scarlett JM, Jobst EE, Enriori PJ, Bowe DD, Batra AK, Grant WF et al. Regulation of central melanocortin signaling by interleukin-1 beta. Endocrinology 2007; 148: 4217–4225.

    Article  CAS  Google Scholar 

  29. Lawrence CB, Rothwell NJ . Anorexic but not pyrogenic actions of interleukin-1 are modulated by central melanocortin-3/4 receptors in the rat. J Neuroendocrinol 2001; 13: 490–495.

    Article  CAS  Google Scholar 

  30. Buller K, Xu Y, Dayas C, Day T . Dorsal and ventral medullary catecholamine cell groups contribute differentially to systemic interleukin-1beta-induced hypothalamic pituitary adrenal axis responses. Neuroendocrinology 2001; 73: 129–138.

    Article  CAS  Google Scholar 

  31. Um JY, Lee KM, Kim HM . Polymorphism of interleukin-1 receptor antagonist gene and obesity. Clin Chim Acta 2004; 340: 173–177.

    Article  CAS  Google Scholar 

  32. Carter MJ, di Giovine FS, Jones S, Mee J, Camp NJ, Lobo AJ et al. Association of the interleukin 1 receptor antagonist gene with ulcerative colitis in Northern European Caucasians. Gut 2001; 48: 461–467.

    Article  CAS  Google Scholar 

  33. Lorentzon M, Swanson C, Andersson N, Mellström D, Ohlsson C . Free testosterone is a positive, whereas free estradiol is a negative, predictor of cortical bone size in young Swedish men: the GOOD study. J Bone Miner Res 2005; 20: 1334–1341.

    Article  CAS  Google Scholar 

  34. Perrier S, Darakhshan F, Hajduch E . IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde? FEBS Lett 2006; 580: 6289–6294.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to J-O Jansson.

Additional information

Supplementary Information accompanies the paper on International Journal of Obesity website (

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Andersson, N., Strandberg, L., Nilsson, S. et al. Variants of the interleukin-1 receptor antagonist gene are associated with fat mass in men. Int J Obes 33, 525–533 (2009).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • anakinra
  • single-nucleotide polymorphism
  • dual-energy X-ray absorptiometry

This article is cited by


Quick links